Company Overview

Savara Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for rare respiratory diseases with significant unmet medical need. The company operates within the biotechnology and pharmaceuticals industry, with its activities centered on research, clinical development, and regulatory advancement of novel biologic therapies rather than commercial product sales.

Savara’s primary value driver is its lead investigational product, molgramostim, an inhaled recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) being developed for autoimmune pulmonary alveolar proteinosis (aPAP). The company has evolved from a broader respiratory-focused development platform into a more concentrated rare-disease strategy following portfolio rationalization and pipeline prioritization. Savara was originally founded in 2007 and has undergone multiple strategic restructurings, including mergers and asset divestitures, to focus on late-stage respiratory assets.

Business Operations

Savara operates as a single operating segment focused on drug development for rare pulmonary diseases. The company does not generate product revenue and instead relies on capital markets financing to fund clinical trials, regulatory activities, and corporate operations. Its core activities include clinical trial execution, manufacturing oversight through third-party contractors, and regulatory engagement with health authorities.

The company’s operations are primarily based in the United States, with clinical trials conducted both domestically and internationally through contract research organizations. Savara controls intellectual property related to molgramostim and manages development internally while outsourcing manufacturing and clinical operations. Data inconclusive based on available public sources regarding any material revenue-generating partnerships or joint ventures currently in place.

Strategic Position & Investments

Savara’s strategy is centered on advancing molgramostim through late-stage clinical development and toward potential regulatory approval as a targeted therapy for aPAP, a rare autoimmune lung disorder with limited treatment options. The company positions itself as a specialist in rare respiratory diseases, emphasizing deep clinical expertise and focused capital allocation rather than a diversified pipeline.

Historically, Savara has made selective acquisitions and in-licensing transactions to build its pipeline, though most non-core assets have since been discontinued or divested. Current investments are primarily directed toward clinical trials, manufacturing scale-up readiness, and regulatory preparation. Data inconclusive based on available public sources regarding active expansion into additional therapeutic areas beyond rare pulmonary diseases.

Geographic Footprint

Savara is headquartered in the United States, with its principal executive offices in Texas. Its operational footprint is relatively lean, reflecting its status as a clinical-stage company, with no commercial infrastructure in place. Clinical development activities extend beyond the U.S. through international trial sites, particularly in Europe, where aPAP prevalence and specialist centers support patient recruitment.

The company does not report owning or operating manufacturing facilities and instead maintains a global operational reach through third-party vendors and research partners. International exposure is primarily related to clinical development and regulatory strategy rather than direct sales or distribution.

Leadership & Governance

Savara is led by an executive team with experience in biotechnology, rare disease drug development, and capital markets. The leadership emphasizes disciplined capital management, regulatory execution, and focus on high-impact orphan indications.

Key executives include:

• Matt Pauls – President and Chief Executive Officer
• David A. Lowrance – Chief Financial Officer
• Eric J. Olson, M.D. – Chief Medical Officer
• Richard J. Hawkins – Chief Operating Officer

The company is governed by a board of directors with backgrounds in pharmaceuticals, finance, and clinical development, supporting Savara’s strategy of advancing a concentrated late-stage respiratory asset toward potential commercialization.